AU2014254086B2 - Pertuzumab variants and evaluation thereof - Google Patents

Pertuzumab variants and evaluation thereof Download PDF

Info

Publication number
AU2014254086B2
AU2014254086B2 AU2014254086A AU2014254086A AU2014254086B2 AU 2014254086 B2 AU2014254086 B2 AU 2014254086B2 AU 2014254086 A AU2014254086 A AU 2014254086A AU 2014254086 A AU2014254086 A AU 2014254086A AU 2014254086 B2 AU2014254086 B2 AU 2014254086B2
Authority
AU
Australia
Prior art keywords
ser
leu
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014254086A
Other languages
English (en)
Other versions
AU2014254086A1 (en
Inventor
Lynn A. Gennaro
Yung-Hsiang Kao
Yonghua Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014254086(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2014254086A1 publication Critical patent/AU2014254086A1/en
Application granted granted Critical
Publication of AU2014254086B2 publication Critical patent/AU2014254086B2/en
Priority to AU2018241141A priority Critical patent/AU2018241141B2/en
Priority to AU2019253804A priority patent/AU2019253804A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44747—Composition of gel or of carrier mixture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
AU2014254086A 2013-04-16 2014-04-15 Pertuzumab variants and evaluation thereof Active AU2014254086B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018241141A AU2018241141B2 (en) 2013-04-16 2018-10-05 Pertuzumab variants and evaluation thereof
AU2019253804A AU2019253804A1 (en) 2013-04-16 2019-10-22 Pertuzumab variants and evaluation thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361812603P 2013-04-16 2013-04-16
US61/812,603 2013-04-16
PCT/US2014/034200 WO2014172371A2 (en) 2013-04-16 2014-04-15 Pertuzumab variants and evaluation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018241141A Division AU2018241141B2 (en) 2013-04-16 2018-10-05 Pertuzumab variants and evaluation thereof

Publications (2)

Publication Number Publication Date
AU2014254086A1 AU2014254086A1 (en) 2015-10-08
AU2014254086B2 true AU2014254086B2 (en) 2018-07-05

Family

ID=50694078

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014254086A Active AU2014254086B2 (en) 2013-04-16 2014-04-15 Pertuzumab variants and evaluation thereof
AU2018241141A Active AU2018241141B2 (en) 2013-04-16 2018-10-05 Pertuzumab variants and evaluation thereof
AU2019253804A Abandoned AU2019253804A1 (en) 2013-04-16 2019-10-22 Pertuzumab variants and evaluation thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018241141A Active AU2018241141B2 (en) 2013-04-16 2018-10-05 Pertuzumab variants and evaluation thereof
AU2019253804A Abandoned AU2019253804A1 (en) 2013-04-16 2019-10-22 Pertuzumab variants and evaluation thereof

Country Status (25)

Country Link
US (8) US9815904B2 (enExample)
EP (3) EP4483964A3 (enExample)
JP (2) JP2016522176A (enExample)
KR (2) KR20200085942A (enExample)
CN (1) CN105121471A (enExample)
AR (1) AR095863A1 (enExample)
AU (3) AU2014254086B2 (enExample)
BR (1) BR112015024926A2 (enExample)
CA (2) CA2907776C (enExample)
CL (3) CL2015003049A1 (enExample)
CR (1) CR20150576A (enExample)
EA (1) EA201591643A1 (enExample)
HK (1) HK1211948A1 (enExample)
IL (2) IL241103B (enExample)
MA (1) MA38567A1 (enExample)
MX (2) MX368259B (enExample)
MY (1) MY173295A (enExample)
NZ (2) NZ712012A (enExample)
PE (2) PE20211214A1 (enExample)
PH (1) PH12015502382A1 (enExample)
RU (2) RU2737727C2 (enExample)
SG (3) SG10201706045RA (enExample)
TW (1) TWI554284B (enExample)
WO (1) WO2014172371A2 (enExample)
ZA (1) ZA201506594B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP4406615A3 (en) 2009-10-26 2024-12-11 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
JP6914336B2 (ja) * 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN110536969A (zh) * 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
EP3682249A4 (en) * 2017-09-13 2021-08-25 Mayo Foundation for Medical Education and Research IDENTIFICATION AND MONITORING OF ACID HYDROLYSIS PRODUCTS FROM IMMUNOGLOBULIN HEAVY CHAINS
JP7259778B2 (ja) 2020-01-31 2023-04-18 トヨタ自動車株式会社 車両、及び自動運転システム
EP3892989A1 (en) * 2020-04-07 2021-10-13 Ares Trading S.A. Capillary gel electrophoresis and its use with complex biological molecules
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
CN117337195A (zh) 2021-04-29 2024-01-02 上海汇连生物医药有限公司 抗体偶联药物的制备方法及应用
KR102511384B1 (ko) 2022-04-14 2023-03-16 지용환 곡물의 손상을 줄일 수 있는 도정기
WO2025021118A1 (zh) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 配体-药物偶联物及其偶联连接子
GB202313175D0 (en) 2023-08-30 2023-10-11 Univ Oxford Innovation Ltd A bivalent polypeptide scaffold and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560111B2 (en) * 2004-07-22 2009-07-14 Genentech, Inc. HER2 antibody composition

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587657D1 (de) 1984-01-30 1993-12-23 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA2055441C (en) 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
DK1187632T3 (da) 1999-05-14 2009-04-06 Genentech Inc Behandling med anti-ErbB2-antistoffer
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
CN100381172C (zh) 1999-06-25 2008-04-16 吉尼泰克公司 使用抗-ErbB2抗体治疗前列腺癌
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PT1282443E (pt) 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
PT1358318E (pt) * 2001-02-07 2007-01-31 Wilex Ag Linha celular de hibridoma g250 e sua utilização para produção de anticorpos monoclonais
CA2481515C (en) 2002-04-10 2013-10-01 Genentech, Inc. Anti-her2 antibody variants
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
HK1078613A1 (zh) 2002-11-21 2006-03-17 Genentech, Inc. 通过抗-erbb2抗体医治非恶性疾病或病患的疗法
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
WO2005099756A2 (en) 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20060067930A1 (en) 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060121044A1 (en) 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP1827603A2 (en) 2004-12-13 2007-09-05 F. Hoffmann-Roche AG Novel pharmaceutical composition containing at least one dolastatin 10 derivative
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
BRPI0712077A2 (pt) 2006-05-01 2012-01-17 Genentech Inc prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa
US8015939B2 (en) 2006-06-30 2011-09-13 Asml Netherlands B.V. Imprintable medium dispenser
BRPI0715829A2 (pt) 2006-08-21 2013-07-23 Hoffmann La Roche terapia de tumor com um anticorpo anti-vegf
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
RU2500686C2 (ru) 2007-03-22 2013-12-10 Дженентек, Инк. АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
CA2687819A1 (en) 2007-06-06 2008-12-11 F.Hoffmann-La Roche Ag Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
MX354993B (es) 2007-07-09 2018-03-28 Genentech Inc Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CA2698541C (en) 2007-10-19 2018-01-09 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
JP2011511777A (ja) * 2008-01-30 2011-04-14 アボット・ラボラトリーズ 抗体断片を結晶化するための組成物及び方法
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
WO2009111707A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011069074A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
CA2782571C (en) * 2009-12-22 2018-01-23 Roche Glycart Ag Anti-her3 antibodies and uses thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
MX2013006392A (es) 2010-12-09 2013-12-06 Genentech Inc Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2746559T3 (es) * 2011-01-28 2020-03-06 Nat Res Council Canada Modificación genética de dominios de inmunoglobulina
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
WO2018085513A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3858333B1 (en) 2017-10-20 2025-11-26 BioNTech SE Preparation and storage of liposomal rna formulations suitable for therapy
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
WO2022013189A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
WO2022125483A1 (en) 2020-12-11 2022-06-16 Genentech, Inc. Combination therapies for treatment of her2 cancer
TW202400230A (zh) 2022-03-14 2024-01-01 美商建南德克公司 乳癌的組合療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560111B2 (en) * 2004-07-22 2009-07-14 Genentech, Inc. HER2 antibody composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARRIS, R. J., Heterogeneity of recombinant antibodies: linking structure to function. DEVELOPMENTS IN BIOLOGICALS, 2005, vol. 122, pages 117-127 *
JUNTTILA, T.T. et al., Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer. CANCER RESEARCH, 2010, vol. 70, no. 11, pages 4481-4489 *

Also Published As

Publication number Publication date
TW201442725A (zh) 2014-11-16
US9815904B2 (en) 2017-11-14
MX2015013898A (es) 2016-07-08
HK1211948A1 (en) 2016-06-03
EP4483964A3 (en) 2025-04-30
CL2015003049A1 (es) 2016-06-10
PE20151769A1 (es) 2015-12-11
RU2015141520A (ru) 2017-05-22
NZ712012A (en) 2020-04-24
EP2986643A2 (en) 2016-02-24
NZ751877A (en) 2020-04-24
CA2907776C (en) 2020-04-14
EP4483964A8 (en) 2025-06-18
US20250084181A1 (en) 2025-03-13
EP4483964A2 (en) 2025-01-01
IL275398A (en) 2020-07-30
US20140308277A1 (en) 2014-10-16
AU2014254086A1 (en) 2015-10-08
CR20150576A (es) 2015-11-20
MY173295A (en) 2020-01-14
AU2018241141A1 (en) 2018-10-25
KR20200085942A (ko) 2020-07-15
EA201591643A1 (ru) 2016-02-29
AR095863A1 (es) 2015-11-18
BR112015024926A2 (pt) 2017-10-10
JP2016522176A (ja) 2016-07-28
RU2737727C2 (ru) 2020-12-02
IL241103B (en) 2020-07-30
CN105121471A (zh) 2015-12-02
SG10201706045RA (en) 2017-08-30
CL2017002445A1 (es) 2018-03-16
WO2014172371A3 (en) 2015-01-08
RU2019115089A (ru) 2019-06-11
CA2907776A1 (en) 2014-10-23
PH12015502382A1 (en) 2016-02-22
MX368259B (es) 2019-09-25
SG10201911353WA (en) 2020-02-27
US20190345258A1 (en) 2019-11-14
US20230047103A1 (en) 2023-02-16
WO2014172371A2 (en) 2014-10-23
JP2020015719A (ja) 2020-01-30
MX2019005151A (es) 2022-06-27
PE20211214A1 (es) 2021-07-05
TWI554284B (zh) 2016-10-21
IL241103A0 (en) 2015-11-30
US12145998B2 (en) 2024-11-19
CL2019002244A1 (es) 2019-11-29
ZA201506594B (en) 2018-11-28
US20180037660A1 (en) 2018-02-08
CA3071678A1 (en) 2014-10-23
MA38567A1 (fr) 2017-09-29
US9969811B2 (en) 2018-05-15
US20200157238A1 (en) 2020-05-21
SG11201508536PA (en) 2015-11-27
AU2019253804A1 (en) 2019-11-14
AU2018241141B2 (en) 2019-11-07
US20180037661A1 (en) 2018-02-08
EP3800204A1 (en) 2021-04-07
KR20150143649A (ko) 2015-12-23
US20180037662A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
US12145998B2 (en) Pertuzumab variants and evaluation thereof
AU2018278327B2 (en) Activatable anti-pdl1 antibodies and methods of use thereof
EP3645571B1 (en) Her3 antigen-binding molecules
CN111375059B (zh) 一种抗gitr抗体药物组合物及其用途
EP4455163A1 (en) Antibody variant with reduced biological activity
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1
HK40026637A (en) Her3 antigen-binding molecules
HK40026637B (en) Her3 antigen-binding molecules

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)